Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million
BUZZ-Biohaven jumps on SK Biopharma epilepsy licensing deal worth up to $795 million Updates
** Shares of drugmaker Biohaven BHVN.N rise 5.4% to $15.15
** Biohaven enters a partnership with South Korean drug maker SK Biopharmaceuticals 326030.KS worth up to $795 million to license and commercialize a new epilepsy drug platform
** SK Biopharmaceuticals gains exclusive global rights to Biohaven's lead epilepsy drug candidate, opakalim
** Opakalim is in mid-to-late stage trial testing for focal epilepsy, and trial results are expected in H2 2026
** Biohaven to use SK's established epilepsy development and sales network to bring opakalim to patients globally
** Biohaven's deal with SK Biopharmaceuticals for Kv7 and opakalim rights resolves a key near-term capital overhang- William Blair
** Biohaven will certainly now generate significantly more near-to-mid-term cash from the launch, than it would have if it launched itself- TD Cowen
** Including session's moves, BHVN up ~32% YTD
(Reporting by Kamal Choudhury and Sneha S K in Bengaluru)
Recent news on Biohaven
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Brief: Biohaven - FDA Accepts Biohaven NDA Resubmission For Vyglxia (Troriluzole) In SCA
Biohaven jumps as FDA takes second look at brain disorder drug
Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean